Why Eli Lilly Is Buying Centessa for $7.8 Billion

Eli Lilly acquired Centessa Pharmaceuticals for $7.8 billion in March 2026, expanding into the sleep disorder drug market. The deal marks Lilly’s strategic push into neuroscience beyond its core diabetes and obesity treatments. Centessa’s lead asset, a potential narcolepsy and idiopathic hypersomnia treatment, drove the acquisition. The drug targets orexin receptors, a novel mechanism addressing unmet needs in sleep disorders. Analysts note Lilly’s aggressive M&A strategy, leveraging Centessa’s pipeline to diversify revenue streams amid patent expirations. The move follows rival pharma firms investing heavily in neuroscience therapies. The acquisition aligns with rising demand for sleep disorder treatments, a market projected to grow significantly. Lilly aims to capitalize on Centessa’s late-stage assets to accelerate commercialization. This deal underscores Lilly’s bet on high-value specialty drugs, reinforcing its dominance in high-margin therapeutic areas beyond metabolic diseases.